Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Chancellor Masters And Scholars Of The University Of Cambridge currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, which focuses the university's current legal interactions on a single official at the patent office. The prosecution is taking place within 1 distinct art unit, suggesting that the university's biological research is classified within a specific technical division. This focused administrative structure allows for a direct and singular approach to managing the university's current intellectual property filings.
The busiest examiner for the portfolio is STUBBS, JOHN THOMAS, who is responsible for 1 busiest examiner pending office action. Since the total number of pending office actions is also 1, this examiner is the sole person currently evaluating the university's active cases. For a practitioner, this means that the success of the current prosecution phase is entirely dependent on the decisions of this one individual. The alignment of 1 distinct examiner and 1 distinct art unit indicates a highly specialized technical focus for the university's current applications. The outcome of this 1 pending office action will be the key measure of the university's immediate progress in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, LIA ELAN | 2 | 64.2% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245540 | ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF | TAYLOR, LIA ELAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685192 | ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF | TAYLOR, LIA ELAN | — |
| 18245540 | ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF | TAYLOR, LIA ELAN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685192 | ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF | TAYLOR, LIA ELAN | 1641 | §112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18245540 | ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF | TAYLOR, LIA ELAN | 1675 | §101§112DP | Non-Final OA | — | Pending | Mar 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Chancellor Masters And Scholars Of The University Of Oxford has 2 pending office actions as of October 2026, spread across 2 art units and 1 examiners.
Lia Elan Taylor has the most, with 2 of The Chancellor Masters And Scholars Of The University Of Oxford's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
